Moreover, Fetuin-A has been associated with inflammation and endothelial dysfunction; specifically, it has been shown that circulating Fetuin-A levels are independently associated with endothelial dysfunction and subclinical atherosclerosis in patients with NAFLD [41], suggesting that this hepatokine may be an important mediator of the atherogenic potential of NAFLD. Here, AHSG is linked to metabolic dysfunction-associated steatotic liver disease.